Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedlineMDLN +2.09%16 EV-to-EBIT is 27.04 as of Aug. 09, 2026, which is 3% above its 10-year median of 26.37. GuruFocus rates MDLN with a GF Score™ of 16/100. The stock has 3 warning signs investors should review. Among 472 Medical Devices & Instruments companies, Medline ranks worse than 68.22% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Medline's Enterprise Value is $48,377 Mil.
Medline's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $1,789 Mil. Therefore, Medline's EV-to-EBIT for today is 27.04.
The historical rank and industry rank for Medline's EV-to-EBIT or its related term are showing as below:
MDLN'
s EV-to-EBIT Range Over the Past 10 Years
Min: 23.12 Med: 26.37 Max: 42.52
Current: 27.04
During the past 4 years, the highest EV-to-EBIT of Medline was 42.52. The lowest was 23.12. And the median was 26.37.
MDLN's EV-to-EBIT is ranked worse than 68.22% of 472
companies
in the Medical Devices & Instruments industry
Industry Median: 19.02
vs MDLN: 27.04
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Medline's Enterprise Value for the quarter that ended in Jun. 2026 was $51,426 Mil.
Medline's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,789 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medline EV-to-EBIT Related Terms
Medline EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Medline's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Medline's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medline EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medline's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Medline's EV-to-EBIT falls into.
Medline's current Enterprise Value is $48,377 Mil.
Medline's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,789 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medline (MDLN) has a EV-to-EBIT of 27.04 as of Aug. 09, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Medline and its competitors. This is near median its historical median of 26.37. Over the past decade, Medline's EV-to-EBIT has ranged from 23.12 to 42.52. According to the industry distribution chart, Medline ranks #322 out of 472 companies in the Medical Devices & Instruments industry, placing it in the top 68.2%.
Is Medline's EV-to-EBIT too high?
Medline's current EV-to-EBIT of 27.04 is near median its 10-year median of 26.37. Over the past 10 years, this metric has ranged from a low of 23.12 to a high of 42.52. The Medical Devices & Instruments industry median EV-to-EBIT is 19.02. Medline's value of 27.04 is 42.2% above this industry median. Based on the distribution chart, Medline ranks #322 out of 472 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Medline has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Medline's EV-to-EBIT compare to RMD and WST?
According to the Medical Devices & Instruments industry distribution chart, Medline ranks #322 out of 472 companies for EV-to-EBIT. This places Medline in the lower half of its industry. The industry median EV-to-EBIT is 19.02. Medline's value of 27.04 is 42.2% above this benchmark. Historically, Medline's own EV-to-EBIT has ranged from 23.12 to 42.52 over the past decade. While the company's 10-year median is 26.37 vs. the industry median of 19.02, Medline has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.02, based on 472 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medline's current EV-to-EBIT of 27.04 is 42.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Medline and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medline's current EV-to-EBIT is 27.04, which is near median its own 10-year median of 26.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medline stock overvalued right now?
Medline (MDLN) has a current EV-to-EBIT of 27.04. The current EV-to-EBIT is 27.04, which is near median its 10-year median of 26.37 and 42.2% above the Medical Devices & Instruments industry median of 19.02. Medline's overall GF Score™ is 16/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Medline (MDLN), the current EV-to-EBIT is 27.04 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medline is the largest provider of medical-surgical products and supply chain solutions in the US. The company generates over 90% of its revenue domestically and serves some of the largest US health systems. Medline offers approximately 190,000 Medline-branded products across more than 250 product families—including front-line care, surgical solutions, and laboratory and diagnostics—as well as roughly 150,000 third-party products sourced from over 1,250 vendors. The company maintains prime vendor relationships with many customers, acting as the primary consolidated logistics partner for their medical-surgical needs. Medline has significant scale, supported by more than 30 manufacturing facilities and a fleet of over 2,000 owned delivery trucks. Medline went public in December 2025.
16GF Score
Get the complete analysis for MDLN
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDLN has been successfully added to your 
